NAMPT has been implicated in the pluripotency and dedifferentiation of CSCs, and several NAMPT inhibitors such as FK-866, GNE-617, GNE-618, CHS-828 have shown antitumor effects in a variety of cancers including colon cancer [13], gastrointestinal cancer [14], prostate cancer [15], breast cancer [16], and thyroid cancer [17]. This evidence concerns the gene NAMPT and prostate carcinoma.